Last reviewed · How we verify
Placebo to match Teriflunomide
Placebo to match Teriflunomide is a Small molecule drug developed by Sanofi. It is currently in Phase 3 development.
Placebos do not have a known mechanism of action.
At a glance
| Generic name | Placebo to match Teriflunomide |
|---|---|
| Sponsor | Sanofi |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Since placebos are inert substances, they do not interact with the body in a way that would produce a therapeutic effect. They are used as a control in clinical trials to compare the efficacy of active treatments.
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) (PHASE3)
- Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) (PHASE3)
- Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (PHASE3)
- Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2) (PHASE3)
- Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1) (PHASE3)
- Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis (PHASE3)
- Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to match Teriflunomide CI brief — competitive landscape report
- Placebo to match Teriflunomide updates RSS · CI watch RSS
- Sanofi portfolio CI
Frequently asked questions about Placebo to match Teriflunomide
What is Placebo to match Teriflunomide?
Placebo to match Teriflunomide is a Small molecule drug developed by Sanofi.
How does Placebo to match Teriflunomide work?
Placebos do not have a known mechanism of action.
Who makes Placebo to match Teriflunomide?
Placebo to match Teriflunomide is developed by Sanofi (see full Sanofi pipeline at /company/sanofi).
What development phase is Placebo to match Teriflunomide in?
Placebo to match Teriflunomide is in Phase 3.
Related
- Manufacturer: Sanofi — full pipeline
- Compare: Placebo to match Teriflunomide vs similar drugs
- Pricing: Placebo to match Teriflunomide cost, discount & access